西罗莫司在肾移植受者中的转换治疗

背景：传统的钙调磷酸酶抑制剂能导致慢性移植肾肾病的发生,新型免疫抑制剂西罗莫司的出现就为替换这一治疗方案提供了可能。目的：验证西罗莫司在肾移植后受者中转换治疗的临床效果及其安全性。方法：对同种异体肾移植后以口服钙调磷酸酶抑制剂为主的60例受者,进行以西罗莫司为主的转换治疗,观察转换后6个月内临床效果、安全性和不良反应。结果与结论：西罗莫司转换治疗后6个月内急性排斥反应发生率为13.3%。因慢性移植肾肾病进行药物转换的受者,转换后肾功能改善;其他转换后移植后肝损害及高血糖有所改善。结果提示西罗莫司在转换治疗时疗效优于钙调磷酸酶抑制剂。

Conversion treatment using sirolimus for kidney transplant recipients

BACKGROUND：Traditional calcium the phosphoric acid enzymes inhibitors can result in a chronic renal transplants kidney disease. Vaccination sirolimus inhibitors provide new substitution for the treatment. OBJECTIVE：To verify the efficacy and safety of conversion treatment of sirolimus for kidney transplant recipients. METHODS：Sixty eligible kidney transplant recipients treated with calcineurin inhibitor as main immunosuppressives were converted to sirolimus. The clinical outcome,complications and side effects were observed. RESULTS AND CONCLUSION：Eight recipients （13.3%） experienced acute rejection. The renal functions of recipients with chronic renal transplants kidney disease were improved after conversion treatment. The liver damage or hyperglycemia also improved in other recipients. The results demonstrated that sirolimus is superior to calcineurin inhibitor in conversion treatment.